glp 1 drugs alcohol Popular weight-loss could take the edge off your buzz, study finds Not just obesity: GLP-1 receptor

Description

For instance, in a rat model of sciatic nerve injury, treatment with exenatide reduced pain behaviors, including hyperalgesia and allodynia [106]

A 20% relative risk reduction in MACE, including myocardial infarction, stroke, and cardiovascular death and a 30% relative risk reduction in hospitalizations for HF (58)

A large retrospective study by Best et al compared patients treated with exenatide, a GLP-1 analog, to those treated with other glucose-lowering drugs, and found a 20% decrease in cardiovascular events

In individuals without diabetes, sensations of bloating/fullness are more closely associated with emptying from the distal stomach and antral area as measured by ultrasound (50)

Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate